Company: ABUS
Filing Date: 2025-04-03
Form Type: 8-K
Source: 0001447028-25-000093
Chunk: 2

Company: Arbutus Biopharma Corp
Filing Date: 2025-04-03
Form: 8-K
Item: Item 8.01
Chunk 2
---
Item 8.01.

Other Events.

As previously disclosed, on February 28, 2022, the Company and Genevant Sciences, Ltd. filed a lawsuit in the U. S. District Court for the District of Delaware (the “ Court”) against Moderna, Inc. and a Moderna affiliate (collectively, “ Moderna”) seeking damages for infringement of U. S. Patent Nos. 8,058,069, 8,492,359, 8,822,668,9,364,435, 9,504,651, and 11,141,378 in the manufacture and sale of MRNA-1273, Moderna’s vaccine for COVID-19. The patents relate to nucleic acid-lipid particles and lipid vesicles, as well as compositions and methods for their use. The lawsuit seeks fair compensation for Moderna’s use of the Company’s patented technology that was developed with great effort and at great expense, without which Moderna’s COVID-19 vaccine would not have been successful. On March 31, 2025, the Court moved the start of the trial from September 24, 2025 to September 29, 2025.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

  ARBUTUS BIOPHARMA CORPORATION                                             
  By:                                /s/ Lindsay Androski                   
  Name:                              Lindsay Androski                       
  Title:                             President and Chief Executive Officer